Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis.

OBJECTIVE To estimate the global burden of chronic pulmonary aspergillosis (CPA) after pulmonary tuberculosis (PTB), specifically in cases with pulmonary cavitation. METHODS PTB rates were obtained from the World Health Organization and a scoping review of the literature was conducted to identify studies on residual pulmonary cavitation after PTB and estimate the global incidence of CPA after PTB. Having established that from 21% (United States of America) to 35% (Taiwan, China) of PTB patients developed pulmonary cavities and that about 22% of these patients developed CPA, the authors applied annual attrition rates of 10%, 15% and 25% to estimate the period prevalence range for CPA over five years. Analysis was based on a deterministic model. FINDINGS In 2007, 7.7 million cases of PTB occurred globally, and of them, an estimated 372,000 developed CPA: from 11,400 in Europe to 145,372 in South-East Asia. The global five-year period prevalence was 1,174,000, 852,000 and 1,372,000 cases at 15%, 25% and 10% annual attrition rates, respectively. The prevalence rate ranged from < 1 case per 100,000 population in large western European countries and the United States of America to 42.9 per 100,000 in both the Democratic Republic of the Congo and Nigeria. China and India had intermediate five-year period prevalence rates of 16.2 and 23.1 per 100,000, respectively. CONCLUSION The global burden of CPA as a sequel to PTB is substantial and warrants further investigation. CPA could account for some cases of smear-negative PTB. Since CPA responds to long-term antifungal therapy, improved case detection should be urgently undertaken.

[1]  J. Smith,et al.  High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Philippe Glaziou,et al.  Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment , 2011, Clinical epidemiology.

[3]  S. Roberts,et al.  Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Amitani,et al.  Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. , 2010, The Journal of infection.

[5]  G. Churchyard,et al.  Excess lung function decline in gold miners following pulmonary tuberculosis , 2010, Thorax.

[6]  D. Denning,et al.  Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma , 2010, European Respiratory Journal.

[7]  Hojoong Kim,et al.  Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  Philippe Glaziou,et al.  Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.

[9]  A. Brik,et al.  Surgical outcome of pulmonary aspergilloma. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  T. Holtz,et al.  Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  C. Hamilton,et al.  The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  Jen-Jyh Lee,et al.  High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculous therapy. , 2008, European journal of radiology.

[13]  D. Denning,et al.  Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. , 2008, The Journal of infectious diseases.

[14]  H. Nunes,et al.  Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. , 2007, Chest.

[15]  D. Denning,et al.  Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis , 2007, Clinical chemistry and laboratory medicine.

[16]  L. Singh,et al.  Surgical treatment of pulmonary aspergilloma: a series of 72 cases. , 2007, The Indian journal of chest diseases & allied sciences.

[17]  Dermot Maher,et al.  International standards for tuberculosis care. , 2006, The Lancet. Infectious diseases.

[18]  Stefan Niemann,et al.  Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance , 2006, PLoS medicine.

[19]  M. Levin,et al.  Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis , 2006, European Respiratory Journal.

[20]  D. Denning,et al.  Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. , 2006, The American journal of medicine.

[21]  D. Denning,et al.  The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. , 2006, The Journal of infection.

[22]  H. Arksey,et al.  Scoping studies: towards a methodological framework , 2005 .

[23]  Y. T. Kim,et al.  Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. , 2005, The Annals of thoracic surgery.

[24]  R. Barker,et al.  Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  D. Denning,et al.  Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Terra Filho,et al.  Pulmonary tuberculosis: tomographic evaluation in the active and post-treatment phases. , 2003, Sao Paulo medical journal = Revista paulista de medicina.

[27]  F. Dias,et al.  Three-year follow-up of patients with pulmonary tuberculosis in Guinea-Bissau, West Africa. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[28]  J. Régnard,et al.  Aspergilloma: a series of 89 surgical cases. , 2000, The Annals of thoracic surgery.

[29]  P. Sonnenberg,et al.  Risk factors for pulmonary disease due to culture-positive M. tuberculosis or nontuberculous mycobacteria in South African gold miners. , 2000, The European respiratory journal.

[30]  C. Connolly,et al.  Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. , 1999, AIDS.

[31]  A. Kok-Jensen,et al.  Tuberculosis treatment in Denmark: treatment outcome for all Danish patients in 1992. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  J. Latgé,et al.  Aspergillus fumigatus and Aspergillosis , 1999, Clinical Microbiology Reviews.

[33]  D. Maher,et al.  An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. , 1998, Bulletin of the World Health Organization.

[34]  L. Severo,et al.  Pulmonary Aspergillus niger intracavitary colonization. Report of 23 cases and a review of the literature. , 1997, Revista iberoamericana de micologia.

[35]  R. Kappe,et al.  Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis , 1996, Mycoses.

[36]  G. Massard,et al.  [Surgical treatment of pulmonary and bronchial aspergilloma]. , 1993, Annales de chirurgie.

[37]  S. Sahn,et al.  Aspergilloma in sarcoid and tuberculosis. , 1987, Chest.

[38]  R. M. Coleman,et al.  Use of the immunodiffusion test in the serodiagnosis of aspergillosis. , 1972, Applied microbiology.

[39]  D. Davies.  Aspergillus in persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. , 1968, Tubercle.

[40]  J. Longbottom,et al.  DIAGNOSTIC PRECIPITIN TEST IN ASPERGILLUS PULMONARY MYCETOMA. , 1964, Lancet.